Is Lion (TSE:4912) Undervalued On Its Oral Care Growth Story?
Recent Performance Snapshot for Lion stock
Lion (TSE:4912) has drawn fresh investor attention after a recent share price move, with the stock last closing at ¥1,898. This price sits alongside a market value of about ¥524.97b.
Over the past month and the past 3 months, Lion has recorded total returns of 14.23% and 23.05%. The stock’s 1 year and 5 year total returns stand at 21.49% and 13.90%, with a year to date figure of 15.73%.
See our latest analysis for Lion.
The recent 7 day share price return of 13.18% and 30 day share price return of 14.23% sit alongside a 1 year total shareholder return of 21.49% and 3 year total shareholder return of 31.22%, which points to momentum building for Lion rather than fading.
If you are weighing Lion’s recent strength against other opportunities, this is a useful moment to scan a focused set of 11 top founder-led companies
After Lion’s sharp move and with the stock at ¥1,898, the gap between this price, analyst targets and intrinsic estimates looks important. Is fair value closer to the current market quote, or to the higher end of the valuation range?
Most Popular Narrative: 3.2% Undervalued
The most followed narrative on Lion currently places fair value at ¥1,960.83, slightly above the last close at ¥1,898. That creates a modest valuation gap for investors to judge against the recent share price strength.
Lion Corporation is focusing on strengthening its Oral Health Care segment as a top priority and aims for an 8% annual growth rate in this area. This strategic emphasis on high-margin Oral Health Care products is expected to positively impact both revenue and net margins.
Investors may want to see what sits behind that push into higher margin oral care and overseas expansion. The narrative leans on measured revenue expectations and stable earnings quality, and it also assumes a richer future earnings multiple than the sector. These elements together are presented as the basis for a higher fair value for Lion.
Result: Fair Value of ¥1,960.83 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Lion narrative still hinges on overseas expansion working smoothly and the shift toward higher margin oral care not being knocked off course by execution issues.
Find out about the key risks to this Lion narrative.
Another View on Lion’s Valuation
The earlier fair value discussion for Lion leaned on analyst earnings forecasts and target prices. On current numbers, Lion trades on a P/E of 18.2x compared with 16.1x for the Asian Household Products industry and a peer fair ratio of 23.5x. That mix of slightly richer pricing than the industry but a discount to the fair ratio raises a practical question. Is the market already paying up for Lion’s quality, or is it still catching up to where that fair ratio suggests pricing could move?
For a closer look at how this valuation gap lines up against earnings quality, pricing versus peers and future expectations, take a moment to review the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Lion is clearly constructive, so it helps to move quickly and test that optimism against the full set of facts. To see what stands out on the positive side, review the 3 key rewards
Looking for more investment ideas beyond Lion?
If Lion has sharpened your focus, do not stop here. Broader opportunities could suit your goals even better, so make sure you scan the wider market now.
- Spot potential bargains early by reviewing screener containing 65 high quality undiscovered gems that may not yet be widely followed but still show strong underlying fundamentals.
- Prioritise resilience by scanning 54 resilient stocks with low risk scores that pair steadier risk profiles with business models built for consistency.
- Strengthen your income core by checking 37 dividend fortresses that offer higher dividend yields alongside support from underlying cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com